Prima BioMed Ltd. announced that Russell J. Howard, PhD, will join its board as a Non-Executive Director with immediate effect. Dr. Howard brings a strong scientific background and significant executive-level industry experience to its board. Dr. Russell Howard is an Australian scientist, CEO, and entrepreneur; he was recently the overall winner of the 2013 Advance Global Australian Award for his global impact on the biotechnology field and green chemistry.

Prima Biomed Ltd. announced that Holbrook Kohrt, MD, PhD and Pamela Klein, MD have been brought on as senior clinical advisors for the CVac development programs. The two professionals will work with Dr. Sharron Gargosky and Prima's management team to guide the ongoing ovarian cancer clinical trials, interpret clinical and immunological data coming from the ongoing CAN-003 trial, and help develop the strategy and clinical design of the planned phase 2 pilot trials of CVac in additional cancer targets. Dr. Pamela Klein is Founder and President of PMK BioResearch and serves as a consultant to industry. With a strong track record of leadership in oncology product development, Dr. Klein has previously served as the Chief Medical Officer at Intellikine, Vice President, Development at Genentech, and served as the Research Director at the U.S. National Cancer Institute's Navy Breast Care Center, among other research and development appointments. Dr. Holbrook Kohrt is a Professor of Medicine, Division of Oncology, at Stanford University School of Medicine. Dr. Kohrt has served as the primary investigator on a number of NIH and industry sponsored oncology trials and has published extensively in the fields of cancer immunology and immunotherapy.

Prima Biomed Ltd. announced consolidated cash flow results for the third quarter and nine months ended March 31, 2013. For the quarter, the company announced net cash flows used in operating activities of AUD 2,857,000. Payment for acquisition of physical non-current assets was AUD 1,000. For the nine months, the company announced net cash flows used in operating activities of AUD 12,759,000. Payment for acquisition of physical non-current assets was AUD 56,000.